{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-21-023320","form_type":"8-K","ticker":"NVNO","cik":"0001661053","company_name":"enVVeno Medical Corp","filed_at":"2021-09-22T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.067624+00:00","generated_at":"2026-06-29T02:05:05.642937+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Hancock Jaffe to rename enVVeno Medical, focus on venous disease; VenoValve trial to start","bullets":["Name change to enVVeno Medical Corporation, tickers NVNO/NVNW effective Oct 1, 2021.","VenoValve SAVVE pivotal trial ready to enroll 75 patients at up to 20 U.S. centers.","Development of second venous disease product 'enVVe' initiated; expected unveil mid-2022.","CoreoGraft cardiac bypass program discontinued to focus on venous disease."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-21-023320","json":"https://secwatch.observer/filing/0001493152-21-023320.json","markdown":"https://secwatch.observer/filing/0001493152-21-023320.md","text":"https://secwatch.observer/filing/0001493152-21-023320.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661053/000149315221023320/0001493152-21-023320-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661053/000149315221023320/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T02:05:05.642937+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}